Genetic Signatures Limited (ASX:GSS)

Market Cap	88.59M
Revenue (ttm)	18.66M
Net Income (ttm)	-22.59M
Shares Out	227.14M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,748,138
Average Volume	200,294
Open	0.3950
Previous Close	0.3950
Day's Range	0.3900 - 0.3950
52-Week Range	0.3600 - 0.8200
Beta	0.66
RSI	28.73
Earnings Date	May 26, 2025

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral men...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: GSS

Financial Performance

In 2024, Genetic Signatures's revenue was 13.77 million, a decrease of -36.00% compared to the previous year's 21.51 million. Losses were -17.86 million, 27.1% more than in 2023.